Aim To assess differences in treatment of ischaemic heart disease in the Seandinavian countries.
Methods and Results The Scandinavian Simvastatin Survival Study (4S) lasted 5.4 years and showed that death rates in 4444 patients with coronary heart disease were 30% lower in those treated with simvastatin to lower serum cholesterol than in those given placebo.
Apart from this main result, the 4S provided detailed information on rates of death and other manifestations of coronary heart disease, as well as on use of non-lipid forms of therapy.
There were substantial differences in 4S placebo group rates of mortality, coronary deaths and major coronary events between countries.
Surgical and medical therapy varied importantly between countries.
Conclusions Major inter-country differences in rates of death and myocardial infarction in patients with coronary heart disease were likely to be due to a composite of differences in baseline characteristics including smoking.
They occurred in a setting of very uneven exploitation of the potential for improving survival of patients with ischaemic heart disease.
Mots-clés Pascal : Cardiopathie coronaire, Homme, Etude comparative, Pays Scandinaves, Europe, Traitement, Chimiothérapie, Chirurgie, Pronostic, Efficacité traitement, Mortalité, Morbidité, Exploration, Appareil circulatoire pathologie
Mots-clés Pascal anglais : Coronary heart disease, Human, Comparative study, Scandinavia, Europe, Treatment, Chemotherapy, Surgery, Prognosis, Treatment efficiency, Mortality, Morbidity, Exploration, Cardiovascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0492161
Code Inist : 002B12A03. Création : 19/02/1999.